Testing New Drugs for Tumors in People With NF2-Related Schwannomatosis
Tests several targeted drugs against progressive tumors in people with NF2-related schwannomatosis.
Key facts
- Who runs it
- Scott R. Plotkin, MD, PhD
- Where
- Baltimore, Boston, Indianopolis, Los Angeles, Miami, and New York, United StatesSee the 6 sites
- Trial code
- Registry title
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 109 people, planned
- Started
- 20 Jun 2020
- Expected to end
- 1 Dec 2030
- Type of study
- Interventional, 3 groups
- Treatments tested
- Brigatinib
- Neratinib
- Retifanlimab
- Bevacizumab
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 or older with NF2-related schwannomatosis whose NF2-related tumor has grown and cannot be treated with surgery.
- Age
- 12 years or older. Retifanlimab plus bevacizumab part: 12 to 25 years.
- Sex
- All sexes can join.
- Disease stage
- NF2-related schwannomatosis with a tumor (vestibular schwannoma, non-vestibular schwannoma, meningioma or ependymoma) that grew within the last 36 months and can be measured. The tumor must not be treatable by surgery because of patient refusal or high surgical risk.
- Earlier treatment
- No chemotherapy in the 4 weeks before joining. No radiation to the target tumor in the last 3 years. No other investigational drugs. Retifanlimab plus bevacizumab part: no bevacizumab or PD-1/PD-L1 inhibitor in the last 180 days.
- Biomarker or test result
- A disease-causing change in the NF2 gene, or a confirmed NF2 diagnosis by NIH or Manchester criteria.
Main reasons for not taking part
- Pregnant women, and women who are breastfeeding
- Tumors likely to need active treatment, including surgery, within 6 months
- Another cancer, unless disease-free for at least 2 years
- Uncontrolled illness such as active infection, heart failure, unstable angina or irregular heartbeat
- Life expectancy under 1 year
The registry criteria, word for word
Show all 113 criteriaShow less
Who can take part
- Patients must have a pathogenic variant in the NF2 gene (either in the germline or in two NF2-related tumors) OR a confirmed diagnosis of NF2 by fulfilling National Institute of Health (NIH) criteria or Manchester criteria:; The NIH criteria includes presence of:
- Bilateral vestibular schwannomas, OR
- First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity; The Manchester criteria includes presence of:
- Bilateral vestibular schwannomas, OR
- First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR
- Unilateral vestibular schwannoma AND any two of: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR
- Multiple meningiomas (two or more) AND unilateral vestibular schwannoma OR any two of: schwannoma, glioma, neurofibroma, cataract; Subjects must have a target NF2-related tumor (VS, non-VS, meningioma, or ependymoma) with documented radiographic progression within the preceding 36 months of Master Study registration defined as either:
- at least 20% increase in volume of enhancing tumor
- at least 2 mm increase in greatest linear dimension of enhancing tumor; Participants must have measurable disease, defined as:
- VS, non-VS, or meningioma target lesions that can be accurately measured as at least 1 ml by volumetric MRI scan or in at least one dimension as ≥10 mm with conventional MRI scan. See protocol for the evaluation of measurable disease
- Ependymoma target lesions measurable linearly; Participant must have a target NF2-related tumor with the following qualities:
- Not amenable to surgery due to patient refusal or due to high risk for surgical complications (e.g., damage to nerve function). Participant must be ≥ 12 years of age on Day 1 of treatment. Life expectancy of greater than 1 year Karnofsky performance status ≥ 70 or ECOG PS 0 or 1 (see Appendix A). Ability to understand and the willingness to sign written informed consent and assent documents
- Must have established relationship with primary care physician and provide contact information
- Participants must meet all eligibility criteria outlined in the Master Study
- Participants must be willing and able to provide written informed consent/assent for the brigatinib arm of the INTUITT-NF2 trial
- Participant is ≥ 12 years of age and has body weight at least 40 kg on Day 1 of treatment
- Patient must be able to swallow pills
- Clinical laboratory values as specified below within 28 days before the first dose of study drug, as described in the protocol document:
- Female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age group and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below:; Female patients must meet 1 of the following:
- Postmenopausal for at least 1 year before the screening visit, or
- Surgically sterile, or
- If they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing of the informed consent form through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse. Brigatinib may decrease effectiveness of hormonal contraceptives, therefore, women are recommended to use non-hormonal methods of contraception. Highly effective non-hormonal birth control for women of child bearing potential with male partners includes:; Sexual abstinence (no sexual intercourse); Intrauterine device (IUD) or intrauterine system (IUS); Bilateral tubal ligation (both tubes tied); Vasectomized partner; Male patients, even if surgically sterilized (i.e., status post-vasectomy) must agree to 1 of the following:
- Practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from heterosexual intercourse
- Participants must be willing and able to provide written informed consent/assent for the retifanlimab-bevacizumab arm of the INTUITT-NF2 trial
- Participants must have a target NF2-related tumor (VS, non-VS, meningioma, or ependymoma) with documented radiographic progression within the preceding 36-months
- Age between 12 and 25 years on day 1 of treatment
- Life expectancy of greater than 1 year
- Participants must meet the following organ and marrow function as defined below:; Leukocytes ≥3000/mcL; Platelets ≥100,000/mcL; Total Bilirubin ≤ 1.5 institutional upper limit of normal (ULN), (<3.0 × institutional ULN for patients with Gilbert Syndrome); AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN; Urine Protein:Creatinine Ratio ≤ 1.9; Glomerular Filtration Rate (GFR) ≥30 mL/min/1.73 m2
- Inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age group and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below:; Female patients must meet 1 of the following:
- Postmenopausal, defined as ≥12 consecutive months of amenorrhea in the absence of endocrine or anti-endocrine therapy, for a minimum of 1 year prior to screening visit, or
- Surgically sterile, or
- If they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing of the informed consent form through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse. Highly effective non-hormonal birth control for women of childbearing potential with male partners may include:
- Sexual abstinence (no sexual intercourse)
- Intrauterine device (IUD) or intrauterine system (IUS)
- Bilateral tubal ligation (both tubes tied)
- Vasectomized partner Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to 1 of the following:
- Practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or
- Completely abstain from heterosexual intercourse
Who cannot take part
- Participants who have had chemotherapy within a minimum of 4 weeks prior to Master Study registration (or a minimum of 5 half-lives and resolution to baseline of toxicities unless there are irreversible toxicities from prior drug that do not influence risk of next drug)
- Participants who have received radiation to the target tumor within the last 3 years prior to Master study registration
- Participants who are receiving any other investigational agents
- Participants with target or non-target nervous system tumors that, in the opinion of the treating investigator, are likely to require active treatment (including surgery) within 6 months of registration to the Master Study
- Treatment with any investigational products within 1 month or 5 half-lives (whichever is longer) before the first dose of study drug
- Had major surgery within 30 days of the first dose of brigatinib. Minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed
- Recovery (ie, to Grade 1 or baseline) from all clinically significant AEs related to prior therapies (excluding alopecia, neuropathy, and nail changes)
- If they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing of the informed consent form through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse. Neratinib may decrease effectiveness of hormonal contraceptives, therefore, women are recommended to use non-hormonal methods of contraception. Highly effective non-hormonal birth control for women of child bearing potential with male partners includes:; Sexual abstinence (no sexual intercourse); Intrauterine device (IUD) or intrauterine system (IUS); Bilateral tubal ligation (both tubes tied); Vasectomized partner; Male patients, even if surgically sterilized (i.e., status post-vasectomy) must agree to 1 of the following:
- Practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from heterosexual intercourse
- Female patients must have negative β-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause. [Women are considered postmenopausal if they are ≥12 months without menses, in the absence of endocrine or anti-endocrine therapies.]
- Treatment with any investigational products within 28 days or 5 half-lives (whichever is longer) before the first dose of study drug
- Had major surgery within 30 days of the first dose of neratinib. Minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed
- Myocardial infarction within 6 months before the first dose of neratinib
- Unstable angina within 6 months before first dose of neratinib
- Congestive heart failure within 6 months before first dose of neratinib
- Had a cerebrovascular accident or transient ischemic attack within 6 months before first dose of neratinib
- Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin, carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or primidone
- Received systemic treatment with certain cytochrome P-450 inhibitors or inducers within 14 days before enrollment; Enrollment Criteria Specific to SUB-STUDY C (retifanlimab plus bevacizumab arm):
- Treatment with any investigational products or chemotherapy within 28 days or 5 half-lives (whichever is longer) before the first dose of study drug
- Treatment with bevacizumab or any PD-1/PD-L1 inhibitor within 180 days before the first dose of study drug
- Had major surgery within 30 days of the first dose of study drug. Minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed
- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to Day 1
- Concurrent use of anti-coagulant drugs (not including prophylactic doses), history of coagulopathy, or evidence of bleeding diathesis or coagulopathy
- Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia
- Immune related toxicity during prior checkpoint inhibitor therapy for which permanent discontinuation of therapy was recommended (per product label or consensus guidelines) or any immune-related toxicity requiring intensive or prolonged immunosuppression to manage (with the exception of endocrinopathy that is well controlled on replacement hormones)
- Active infections requiring systemic antibiotics or antifungal or antiviral treatment within 10 days before first dose of study treatment
- Has received a live vaccine within 28 days before the planned start of study treatment (with the exception of COVID-19 vaccines); Note: Examples of live vaccines include but are not limited to measles, mumps, rubella, varicella-zoster (chickenpox), yellow fever, rabies, BCG, and typhoid vaccines. Seasonal influenza vaccines for injection are generally killed-virus vaccines and are allowed; however, intranasal influenza vaccines are live, attenuated vaccines and are not allowed
- Inadequately controlled HTN (defined as an average systolic blood pressure >160 or an average diastolic blood pressure > 100 for adult patients ≥ 21 years and as an average systolic BP > 130 or an average diastolic blood pressure >80 for pediatric patients 12-21 years) despite adequate treatment with medications. Patients with hypertension should be under treatment on study entry to control blood pressure
- History of a different malignancy, unless (a) have been disease-free for at least 2 years and are deemed by the treating investigator to be at low risk for recurrence of that malignancy
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
- Have significant, uncontrolled, or active cardiovascular disease (as outlined in the protocol):
- Have uncontrolled hypertension (defined as an average systolic blood pressure >160 or an average diastolic blood pressure >100 for adults; for children: please refer to table in protocol; Eligibility Criteria Specific to SUB-STUDY B (Neratinib arm):
- Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
- Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
- History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician
- Any history of clinically significant ventricular arrhythmia
- Have a known history of HIV infection. Testing is not required in the absence of history
- Have malabsorption syndrome or other GI illness that could affect oral absorption of neratinib. Note: This includes any predisposing chronic condition resulting in baseline grade 2 or higher diarrhea
- History of severe allergic reactions or intolerability attributed to compounds of similar chemical or biologic composition to neratinib
- Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of neratinib
- History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to retifanlimab or bevacizumab
- Serious or non-healing wound, ulcer, or bone fracture
- Imaging (CT or MRI) evidence of hemorrhage deemed significant by the treating physician (> grade 1). Subjects with significantly increased risk of CNS hemorrhage are not eligible
- Evidence of interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis
- Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg/day of prednisone or equivalent); Physiologic corticosteroid replacement therapy at doses ≤ 10 mg/day of prednisone or equivalent for adrenal or pituitary insufficiency and in the absence of active autoimmune disease is permitted; Participants with asthma that requires intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections may participate; Participants using topical, ocular, intra-articular, or intranasal corticosteroids (with minimal systemic absorption) may participate; Brief courses of corticosteroids for prophylaxis (eg, contrast dye allergy) or study treatment-related standard premedications are permitted
- History of organ transplant, including allogeneic stem cell transplantation
- Clinically significant cardiovascular disease, such as:
- History of CVA within 12 months of registration
- Myocardial infarction or unstable angina within 12 months of registration
- New York heart association grade II or greater congestive heart failure
- Serious and inadequately controlled cardiac arrhythmia
- Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection)
- Clinically significant peripheral vascular disease
- Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug (if applicable)
- Clinical laboratory values as specified below within 14 days before the first dose of study drug:
- ALT/aspartate aminotransferase (AST) ≤ 2.5 × institutional upper limit of normal (ULN)
- Total serum bilirubin ≤ 1.5 × institutional ULN (<3.0 × institutional ULN for patients with Gilbert syndrome)
- Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2, using the modification of diet in renal disease (MDRD) equation
- Serum lipase ≤1.5 × institutional ULN
- Absolute neutrophil count ≥1.5 × 109/L
- Platelet count ≥75 × 109/L
- Hemoglobin ≥9 g/dL
- Left ventricular ejection fraction (LVEF) ≥50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
- Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug (if applicable)
- QTc interval >0.450 seconds (males) or >0.470 (females), or known history of QTc prolongation or Torsade de Pointes (TdP)
- Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period prior to registration
- Participant must be ≥ 12 years of age and have body weight ≥ 40 kg on Day 1 of treatment
- It is not known what effects neratinib has on human pregnancy or development of the embryo or fetus. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age group and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below:; Female patients must meet 1 of the following:
- Pregnant women are excluded from this study because the experimental agents may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these experimental agents, breastfeeding should be discontinued if the mother is treated; Eligibility Criteria Specific to SUB-STUDY A (Brigatinib arm): CLOSED TO ENROLLMENT
- Participants must be willing and able to provide written informed consent/assent for the neratinib arm of the INTUITT-NF2 trial
- Patient must be able to swallow pills
- Postmenopausal for at least 1 year before the screening visit, or
- Surgically sterile, or
Other criteria
- Eligibility Specific For MASTER PROTOCOL:
Where in United States
- Johns Hopkins HospitalBaltimore, United StatesContact: Jaishri Blakeley, MDTaking people
- Massachusetts General HospitalBoston, United StatesContact: Scott Plotkin, MDTaking people
- Indiana University School of MedicineIndianopolis, United StatesContact: Steven Rhodes, MD, PhDNot yet recruiting
- UCLA Medical CenterLos Angeles, United StatesContact: Phioanh (Leia) Nghiemphu, MDTaking people
- University of MiamiMiami, United StatesContact: Christine Dinh, MDTaking people
- New York University Langone Medical CenterNew York, United StatesContact: Kaleb Yohay, MDTaking people
About the trial
What the trial wants to find out
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas.
Read full original descriptionShow less
This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2-SWN to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies.
* Investigational Drug Sub-study A: Brigatinib * Investigational Drug Sub-study B: Neratinib * Investigational Drug Sub-study C: Retifanlimab plus bevacizumab
The 3 groups in the trial
- Sub-study A (brigatinib) - CLOSED TO ENROLLMENTTreatment being tested
Subjects treated in this arm will receive brigatinib 90 mg by mouth daily for 7 days and then increased to 180 mg by mouth daily if the drug is tolerated.
Treatment: Brigatinib
- Sub-study B (neratinib)Treatment being tested
The first three participants treated in this arm will receive neratinib 200 mg mg by mouth daily. If these participants tolerate the medication well, subsequent participants will receive neratinib 240 mg by mouth daily.
Treatment: Neratinib
- Experimental: sub-study C (retifanlimab plus bevacizumab)Treatment being tested
Subjects on this arm will receive retifanlimab by IV infusion at a dose of 375 mg every 3 weeks on a continuous schedule for 48 weeks. Subjects will also receive bevacizumab by IV infusion at a dose of 7.5 mg/kg every 3 weeks on an intermittent schedule. One cycle last 42 days and the study will last for 52 total weeks (48 treatment weeks and 4 follow-up weeks).
Treatment: Retifanlimab and Bevacizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- Plain-language title
- Testing New Drugs for Tumors in People With NF2-Related SchwannomatosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors.The New England journal of medicine, 2024
- Record updated
- 12 November 2026